Nisa Investment Advisors LLC Grows Stake in Insulet Co. (NASDAQ:PODD)

Nisa Investment Advisors LLC lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 195.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,098 shares of the medical instruments supplier’s stock after purchasing an additional 2,049 shares during the period. Nisa Investment Advisors LLC’s holdings in Insulet were worth $672,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of PODD. Moneta Group Investment Advisors LLC boosted its position in Insulet by 101,333.5% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier’s stock worth $382,818,000 after acquiring an additional 1,299,095 shares during the last quarter. Geode Capital Management LLC boosted its position in Insulet by 55.4% during the first quarter. Geode Capital Management LLC now owns 1,486,725 shares of the medical instruments supplier’s stock worth $473,166,000 after acquiring an additional 529,926 shares during the last quarter. Clearbridge Investments LLC boosted its position in Insulet by 38.8% during the first quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after acquiring an additional 474,545 shares during the last quarter. William Blair Investment Management LLC boosted its position in Insulet by 145.1% during the third quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier’s stock worth $116,894,000 after acquiring an additional 433,884 shares during the last quarter. Finally, Norges Bank acquired a new position in Insulet during the fourth quarter worth about $105,275,000.

Insider Buying and Selling

In related news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.80% of the stock is owned by insiders.

Insulet Price Performance

Shares of PODD opened at $172.71 on Wednesday. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $335.91. The firm’s 50 day moving average price is $175.79 and its 200 day moving average price is $178.99. The company has a market cap of $12.09 billion, a P/E ratio of 59.35, a PEG ratio of 3.15 and a beta of 0.98. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The firm had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. During the same period in the prior year, the firm earned $0.55 EPS. The firm’s revenue for the quarter was up 37.9% on a year-over-year basis. On average, research analysts forecast that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PODD shares. Robert W. Baird upgraded shares of Insulet from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $180.00 to $238.00 in a report on Thursday, December 21st. Stifel Nicolaus boosted their target price on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Piper Sandler decreased their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. JPMorgan Chase & Co. boosted their target price on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Finally, Barclays decreased their target price on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a report on Monday, February 26th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $250.33.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.